Genetic Pathways Behind Liver Fat

Evidence

Metabolic dysfunction-associated steatotic liver disease, or MASLD, involves excess fat in liver cells. Three primary studies approached that accumulation from different directions: a human genetic association followed by a mouse knock-in model, a polygenic-risk experiment in human-derived hepatic cells, and a full-text perturbation study in mice and mouse cell lines. Together they examine fatty-acid entry, mitochondrial maintenance, and lipid oxidation rather than treating genetic risk as a diagnosis by itself.

The July 17 SAMM50 study began with genome-wide and phenome-wide analyses across large biobank cohorts. The researchers reported a significant association between MASLD and rs3761472, a population-enriched single-nucleotide variant in SAMM50. The ingested abstract does not provide the cohort sizes or association effect estimate, so it supports the direction of the association but not a quantitative risk claim.

To test function, the team used CRISPR/Cas9 to create mice carrying a D110G substitution corresponding to rs3761472. The knock-in mice showed impaired clearance of damaged mitochondria, reduced ATP production, higher oxidative stress and inflammatory activation, and disrupted mitochondrial organization in liver. Under a high-fat diet, the variant was accompanied by steatosis, liver injury, insulin resistance, and glucose intolerance. This supplies experimental causality in a mouse model; it does not establish that the variant alone causes human MASLD.

A second July study modeled distributed genetic risk rather than one variant. Researchers genotyped 92 human skin-derived precursor cell lines using a polygenic risk score for hepatic fat content. They selected five lines per risk category, differentiated them into hepatic progenitor-like cells, and exposed them to control or disease-related conditions. Lipid accumulation correlated positively with the score in both conditions. High-score cultures also showed greater fatty-acid uptake and more interleukin-6 secretion.

RNA sequencing predicted stronger CD36 signaling as an upstream feature of the high-risk cells. CD36 helps transport fatty acids into cells. Silencing CD36 with small interfering RNA reduced lipid accumulation in high-score cultures and attenuated expression of genes related to lipid synthesis, breakdown, and inflammation. Because only the abstract was reusable for this briefing, the exact score composition, category sizes, effect magnitudes, and statistical intervals cannot be independently assessed here.

The commercially reusable full-text study tested a mitochondrial lipid-processing pathway in male mice fed a high-fat diet and in mouse cell models. Its compound intervention reduced lipid accumulation while increasing cellular oxygen consumption and PGC-1α, a marker linked to mitochondrial biogenesis; CD36 and fatty-acid synthase protein levels fell. Proteome-wide thermal-shift screening identified 32 candidate interacting proteins among 4,560 quantified proteins. Follow-up assays supported interactions with the fatty-acid oxidation proteins HADHA, HADHB, ACADL, and ACADM, with the authors focusing on HADHA.

HADHA knockdown lowered mitochondrial oxygen consumption and removed much of the intervention-associated change in respiration and lipid-pathway proteins. It also reduced lipid droplets under the tested cell conditions, an important complication: less oxidation and less stored lipid occurred together. The study therefore maps a manipulable mitochondrial node, but it does not show a simple one-direction relationship between HADHA activity and liver fat.

Analysis

The cross-study convergence is a research hypothesis, not an established human disease pathway. The SAMM50 experiment links a single associated variant to mitochondrial organization, damaged-mitochondria clearance, energy production, and diet-sensitive liver injury in mice. The polygenic-risk model reaches a related phenotype from the other side of the balance sheet: genetically higher-risk human-derived cells took up more fatty acid, accumulated more lipid, and implicated CD36. The full-text study independently places CD36 within a broader network containing mitochondrial biogenesis and HADHA-dependent oxidation. Taken together, the results suggest an intake-versus-processing framework in which inherited susceptibility may promote liver fat through several bottlenecks rather than one universal gene. CD36 is the clearest point of cross-study overlap, while SAMM50 and HADHA represent distinct mitochondrial functions. That pattern is informative because it separates convergence at the pathway level from identity at the gene level. A useful next test would compare these nodes in the same human hepatocyte system and determine whether genotype-specific effects persist across nutritional conditions. Until then, the apparent network remains preclinical and partly inferred across unlike experiments.

Limitations

None of the studies demonstrates clinical benefit, predicts an individual outcome, or validates a human intervention. The two July reports were available to ingestion only as abstracts. The SAMM50 abstract omits biobank sample sizes, ancestry composition, effect estimates, and confidence intervals; its functional evidence comes from a CRISPR knock-in mouse exposed to a high-fat diet. The polygenic study began with 92 cell lines but tested five per risk category in hepatic progenitor-like cells, not mature liver tissue, and the pack lacks full methods and numerical effect sizes.

The full-text study used male mice and mouse cell lines, with six animals reported per group and limited treatment durations. Its binding and knockdown experiments do not prove that HADHA has the same role in genetically diverse human liver. The counterintuitive combination of reduced oxygen consumption and reduced lipid droplets after HADHA knockdown also argues against a simple pathway story. Replication in primary human liver models, prespecified genotype comparisons, quantitative mediation tests, and longitudinal human data would be needed to establish whether the proposed intake-processing network explains disease progression.